Lewy body Dementia - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Lewy body Dementia - Pipeline Review, H1 2016', provides an overview of the Lewy body Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lewy body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lewy body Dementia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Lewy body Dementia - The report reviews pipeline therapeutics for Lewy body Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Lewy body Dementia therapeutics and enlists all their major and minor projects - The report assesses Lewy body Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Lewy body Dementia Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Lewy body Dementia Overview 6 Therapeutics Development 7 Pipeline Products for Lewy body Dementia - Overview 7 Lewy body Dementia - Therapeutics under Development by Companies 8 Lewy body Dementia - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Lewy body Dementia - Products under Development by Companies 12 Lewy body Dementia - Companies Involved in Therapeutics Development 13 Axovant Sciences Ltd. 13 BioArctic Neuroscience AB 14 Immungenetics AG 15 Sumitomo Dainippon Pharma Co., Ltd. 16 Lewy body Dementia - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 23 Drug Profiles 25 BAN-0805 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 nelotanserin - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 RVT-101 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 zonisamide - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Lewy body Dementia - Recent Pipeline Updates 32 Lewy body Dementia - Dormant Projects 35 Lewy body Dementia - Product Development Milestones 36 Featured News & Press Releases 36 Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of Nelotanserin For Lewy Body Dementia 36 Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia 37 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
Number of Products under Development for Lewy body Dementia, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Lewy body Dementia - Pipeline by Axovant Sciences Ltd., H1 2016 13 Lewy body Dementia - Pipeline by BioArctic Neuroscience AB, H1 2016 14 Lewy body Dementia - Pipeline by Immungenetics AG, H1 2016 15 Lewy body Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 16 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Stage and Target, H1 2016 19 Number of Products by Stage and Mechanism of Action, H1 2016 21 Number of Products by Stage and Route of Administration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Lewy body Dementia Therapeutics - Recent Pipeline Updates, H1 2016 32 Lewy body Dementia - Dormant Projects, H1 2016 35
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.